Patents Assigned to CUROCELL INC.
  • Enhanced immune cells using dual shRNA and composition including the same
    Patent number: 12285438
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: April 29, 2025
    Assignees: CUROCELL INC., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Chan Hyuk Kim, Young-Ho Lee, Yujean Lee, HyeongJi Lee, Sang Hoon Lee
  • ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME
    Publication number: 20230381236
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.
    Type: Application
    Filed: May 15, 2023
    Publication date: November 30, 2023
    Applicants: CUROCELL, INC., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Chan Hyuk KIM, Young-Ho LEE, Yujean LEE, HyeongJi LEE, Sang Hoon LEE
  • Enhanced immune cells using dual shRNA and composition including the same
    Patent number: 11679129
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: June 20, 2023
    Assignees: CUROCELL, INC., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Chan Hyuk Kim, Young-Ho Lee, Yujean Lee, HyeongJi Lee, Sang Hoon Lee
  • ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME
    Publication number: 20220348871
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.
    Type: Application
    Filed: March 22, 2022
    Publication date: November 3, 2022
    Applicants: CUROCELL INC., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Chan Hyuk KIM, Young-Ho LEE, Yujean LEE, HyeongJi LEE, Sang Hoon LEE, Sang Hoon LEE
  • ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME
    Publication number: 20220348928
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of two genes that weaken the function of the immune cell.
    Type: Application
    Filed: July 16, 2020
    Publication date: November 3, 2022
    Applicants: CUROCELL INC., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Gun Soo KIM, Mi Kyung KIM, Chan Hyuk KIM, Young-Ho LEE, HyeongJi LEE
  • ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME
    Publication number: 20210260119
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.
    Type: Application
    Filed: March 18, 2021
    Publication date: August 26, 2021
    Applicants: CUROCELL INC., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Chan Hyuk KIM, Young-Ho LEE, Yujean LEE, HyeongJi LEE, Sang Hoon LEE
  • ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME
    Publication number: 20210060067
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.
    Type: Application
    Filed: January 10, 2019
    Publication date: March 4, 2021
    Applicants: CUROCELL INC., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Chan Hyuk KIM, Young-Ho LEE, Yujean LEE, HyeongJi LEE, Sang Hoon LEE